
Taysha Gene Therapies Inc
NASDAQ:TSHA

Taysha Gene Therapies Inc
Operating Income
Taysha Gene Therapies Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
Operating Income
-$86.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-139%
|
CAGR 10-Years
N/A
|
|
![]() |
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-3%
|
|
![]() |
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
Taysha Gene Therapies Inc
Glance View
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

See Also
What is Taysha Gene Therapies Inc's Operating Income?
Operating Income
-86.6m
USD
Based on the financial report for Dec 31, 2024, Taysha Gene Therapies Inc's Operating Income amounts to -86.6m USD.
What is Taysha Gene Therapies Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-139%
Over the last year, the Operating Income growth was -21%. The average annual Operating Income growth rates for Taysha Gene Therapies Inc have been 21% over the past three years , -139% over the past five years .